Chemocentryx Inc., of Mountain View, Calif., reported findings from two studies at the European Renal Association – European Dialysis and Transplant Association meeting in Madrid, Spain, including results from an open-label phase II pilot study testing complement 5a receptor inhibitor avacopan (CCX-168) in IgA nephropathy patients, which showed reduced levels of protein in the urine in six of seven patients receiving the drug, at the end of a 12-week period following treatment.